Introduction: Lower back pain (LBP) is a condition that restricts occupational activities of the patients suffering from it owing to pain and its perception, thus severely impacting functional capacity. The economic burden of LBP could be represented directly by the high costs of health care that one has to spend for the symptomatic relief from pain and indirectly due to decreased productivity owing to absenteeism. Material & Method: LBP can be acute, subacute or chronic in duration, however, with conservative measures that includes timely diagnosis and right treatment, the symptoms of low back pain typically improved within a few weeks from onset. Common attributes of LBP are muscular tension and spasms. Result: Pharmacological interventions for the treatment of LBP generally includes non-steroidal anti-inflammatory drugs (NSAIDs) and muscle relaxants, wherein both muscle relaxants and NSAIDs have proven efficacy and safety. Studies have shown that combining NSAIDs with a muscle relaxant could be a better treatment option than NSAIDs alone. One such example is Robi D, which is a combination of muscle relaxant methocarbamol and NSAID diclofenac, indicated for the relief of pain and inflammation associated with LBP along with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis. Conclusion: Although there are no individual studies that have assessed the efficacy and safety of Robi D, the individual efficacy and safety of its components speaks volumes of its durability both in real world and clinical trial. Robi D Injection may be administered during acute or severe phase up to a maximum of 3 days or less until amelioration of acute symptoms, post while the patients could be kept on a maintenance therapy with oral Robinaxol D tablets that contain methocarbamol (muscle relaxant) + diclofenac potassium (analgesic) + paracetamol (analgesic).

Keywords: Methocarbamol; Diclofenac; Low Back Pain.